A SIMPLE AND COST EFFECTIVE CERVICAL CANCER VACCINE

一种简单且具有成本效益的宫颈癌疫苗

• 批准号: 7952389
• 负责人: Frank Bedu-Addo
• 金额: $ 128.09万
• 依托单位: PDS BIOTECHNOLOGY CORPORATION
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952389
• 关键词: SIMPLE; COST; EFFECTIVE; CERVICAL; CANCER

PDS Biotechnology Corporation has developed a simple and cost effective novel prototype nanoparticle immunotherapy to treat cancers caused by infection with the human papillomavirus (HPV). VersamuneTM HPV. The formulation is based on the company's platform technology (VersamuneTM) consisting of nanoparticles composed of the positively charged lipid DOTAP. The nanoparticles facilitate uptake of the HPV protein or peptide antigen incorporated into the nanoparticles by the major antigen presenting cells of the immune system, the dendritic cells. The nanoparticles also act as a potent adjuvant (immune stimulator) without the significant inflammatory responses induced by current adjuvants. The dual function of the nanoparticles has resulted in a very simple, safe and cost effective therapeutic vaccine formulation consisting only of the nanoparticles and the disease-associated HPV protein or peptide antigens. The novel nanoparticle HPV-immunotherapeutic has demonstrated potent curative efficacy both in animals and in human models of cervical cancer.

PDS Biotechnology Corporation 开发了一种简单且具有成本效益的新型原型纳米颗粒免疫疗法，用于治疗由人乳头瘤病毒 (HPV) 感染引起的癌症。 VersamuneTM HPV。该配方基于该公司的平台技术（VersamuneTM），由带正电荷的脂质DOTAP组成的纳米颗粒组成。纳米颗粒促进免疫系统的主要抗原呈递细胞、树突细胞摄取掺入纳米颗粒中的HPV蛋白或肽抗原。纳米颗粒还可以作为有效的佐剂（免疫刺激剂），而不会引起现有佐剂引起的显着炎症反应。纳米粒子的双重功能导致了一种非常简单、安全且具有成本效益的治疗性疫苗制剂，其仅由纳米粒子和与疾病相关的HPV蛋白或肽抗原组成。这种新型纳米颗粒 HPV 免疫治疗药物在动物和人类宫颈癌模型中均显示出有效的疗效。